The European Medicines Agency (EMA) has started examining a request from Pfizer and BioNTech for the administration of a booster dose of the anti-covid vaccine to young people aged 12 to 15, a- she indicated.
“The EMA has started to assess a request for the use of a booster dose of Comirnaty in adolescents aged 12 to 15 years,” the European medicines regulator said in a statement, noting that a request for use in adolescents aged 16 to 17 is also in progress.
The European Center for Disease Prevention and Control (ECDC), according to its English acronym, published a report on Tuesday indicating that booster vaccination significantly increased protection against symptomatic coronavirus infection, compared to primary vaccination.
However, he pointed out that there was currently too little evidence of a possible weakening of the immunity of adolescents after the primary vaccination.
Available data suggest that vaccine efficacy against symptomatic infection begins to decline after five to six months. As for the weakening of immunity in the face of severe forms of the disease, there is currently no scientific proof, according to the ECDC.
.
